CRIS Current Research Information System

LUATTI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.487
AS - Asia 2.098
EU - Europa 1.766
AF - Africa 130
SA - Sud America 90
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.466
VN - Vietnam 713
CN - Cina 530
SG - Singapore 492
GB - Regno Unito 438
SE - Svezia 292
DE - Germania 233
IT - Italia 219
FR - Francia 105
IN - India 97
HK - Hong Kong 94
UA - Ucraina 85
RU - Federazione Russa 82
NL - Olanda 78
BR - Brasile 63
IE - Irlanda 55
FI - Finlandia 36
TG - Togo 35
EE - Estonia 34
KR - Corea 34
ZA - Sudafrica 33
JP - Giappone 30
CH - Svizzera 29
JO - Giordania 28
BG - Bulgaria 26
CI - Costa d'Avorio 25
BE - Belgio 18
CA - Canada 16
PH - Filippine 16
SC - Seychelles 13
TH - Thailandia 12
AR - Argentina 10
NG - Nigeria 10
GR - Grecia 9
IR - Iran 9
BD - Bangladesh 8
CL - Cile 6
IQ - Iraq 6
AT - Austria 5
PL - Polonia 5
TR - Turchia 5
TW - Taiwan 5
EC - Ecuador 4
KE - Kenya 4
LT - Lituania 4
RO - Romania 4
AU - Australia 3
ID - Indonesia 3
IL - Israele 3
LB - Libano 3
MA - Marocco 3
MX - Messico 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
VE - Venezuela 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
ES - Italia 1
GM - Gambi 1
KH - Cambogia 1
LY - Libia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.577
Salva come PNG Salva come JPEG
Città #
Southend 378
Singapore 346
Fairfield 267
Ashburn 247
Chandler 247
Dong Ket 241
Woodbridge 140
Seattle 128
Wilmington 127
Ann Arbor 119
Houston 117
Ho Chi Minh City 104
San Jose 103
Cambridge 97
Hong Kong 88
Hefei 84
Beijing 79
Hanoi 75
Princeton 72
Boardman 57
Dublin 55
Jacksonville 52
Santa Clara 52
Nanjing 37
Lomé 35
Padova 34
Westminster 34
Helsinki 32
New York 32
Berlin 31
Lauterbourg 31
Turin 31
Seoul 30
Bologna 28
Dallas 28
Amman 27
Bern 27
Sofia 26
Abidjan 24
Florence 24
Bremen 23
Tokyo 23
Saint Petersburg 19
Brussels 18
Jinan 18
Munich 18
Redondo Beach 18
Milan 17
Frankfurt am Main 16
Los Angeles 15
Buffalo 14
Guangzhou 14
Shenyang 14
Hebei 12
Nanchang 12
Falkenstein 11
Hangzhou 11
São Paulo 11
Abeokuta 10
Castelfranco Emilia 10
San Diego 10
Da Nang 9
Falls Church 9
Phoenix 9
Can Tho 8
Des Moines 8
Haiphong 8
Redwood City 8
Tianjin 8
Zhengzhou 8
Brooklyn 7
Changsha 7
Düsseldorf 7
Mahé 7
Mountain View 7
Mülheim 7
Orem 7
Shanghai 7
Haikou 6
Hyderabad 6
Jiaxing 6
London 6
Nuremberg 6
Paris 6
Taizhou 6
Wuhan 6
Bengaluru 5
Chengdu 5
Ningbo 5
Taiyuan 5
Toronto 5
Verona 5
Xi'an 5
Boston 4
Council Bluffs 4
Long Xuyen 4
New Delhi 4
Norwalk 4
Olalla 4
Santiago 4
Totale 4.342
Salva come PNG Salva come JPEG
Nome #
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 341
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 257
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 251
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 241
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 239
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 207
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 206
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 194
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 192
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 185
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 182
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 179
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 176
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 175
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 175
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 173
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 162
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 157
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 153
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 153
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 152
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 140
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 134
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 122
Differences among young adults, adults and elderly chronic myeloid leukemia patients 115
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 114
null 104
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 104
null 102
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 93
null 81
null 77
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 44
Totale 6.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.561
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021396 0 0 0 0 0 0 0 0 0 23 35 338
2021/2022819 126 12 52 96 65 38 13 47 31 77 143 119
2022/2023953 110 159 57 119 62 75 22 52 148 20 89 40
2023/2024241 7 28 17 34 18 73 12 13 4 9 16 10
2024/2025797 31 107 57 55 117 43 73 27 1 120 28 138
2025/20261.582 160 148 167 115 192 84 151 57 387 121 0 0
Totale 6.685